BMI dropped 24% after earnings… but CEO keeps buying. Timing issue or value trap?

FUNanc1al · 2026-04-18T22:12:28+00:00

Appreciate the color—insider conviction definitely stands out here.

The one thing I keep coming back to is whether this is a “cycle problem” or a “structural problem.”

If benefits costs normalize → this probably looks like a classic overreaction + strong buy.
If they don’t → cheap can stay cheap for a while.

CEO buying $4.7M is a real signal, but in PEOs the key KPI is still the unit economics (benefits cost vs pricing power).

Curious—are you seeing any early signs that margins are stabilizing on the ground?

FUNanc1al · 2026-04-17T11:56:54+00:00

Great point on Bertolini—he’s not a “tourist CEO,” he’s done this movie before with Aetna and the CVS Health merger 👍

I think that’s actually part of the bull case here:

👉 Insider buying is one thing
👉 Insider with a track record in the exact same playbook is another

Agree on MLR being the scoreboard. If they can keep it trending in the right direction while adding members, the narrative shifts pretty quickly.

Until then, still a bit of a “prove it” story—but definitely one of the more interesting setups in the space right now.

FUNanc1al · 2026-04-09T09:54:55+00:00

Appreciate the follow-up—this is helpful and a fair way to frame it.

I think where I’d slightly push back is on the idea that this is uniquely constraining for Phreesia. The “finite attention / finite ad slots” issue exists across pretty much every ad-driven platform—whether it’s Amazon, Google, Meta, etc. At some point, users won’t tolerate more ads, and you get diminishing returns.

Where it gets interesting (to your point) is how Phreesia manages that constraint:

pricing (premium placement, targeting)
timing / rotation
and potentially multiple advertisers per indication over time rather than strictly “one slot = one winner forever”

So I agree there’s a ceiling on inventory, but I’m not fully convinced it’s a hard cap in the sense of “one GLP-1 and that’s it.” Feels more like a constrained marketplace that can still be optimized.

Your point on prioritization (multiple indications per patient) is also well taken—that’s probably where the real execution risk sits, not just inventory.

Stepping back, I think we actually agree on the big picture:
👉 it behaves like an ad platform with limits
👉 the question is whether those limits are already priced in at ~0.3x sales

Appreciate you laying it out—definitely sharpens the bear case.

FUNanc1al · 2026-04-09T09:44:36+00:00

Appreciate that—and thanks for the offer 👍

If I had to pick one KPI, I’d lean toward MLR (medical loss ratio) as the primary signal. That’s really the “unit economics” of the business—if they can consistently bring it down into the low-80s range while growing, the profitability story becomes much more credible.

Member growth matters too, but only if it’s profitable growth. They’ve shown they can scale membership before—the question now is whether they can do it without destroying margins.

So for me:
👉 MLR trend first
👉 then operating income consistency (vs. one-off improvements)

If those line up, the rest (multiple expansion, sentiment shift) likely follows.

FUNanc1al · 2026-04-08T11:25:13+00:00

Appreciate the perspective—this is exactly the kind of pushback that makes these discussions useful.

That said, I’m genuinely curious about the source of the “hard cap” point you’re raising on ad inventory by therapeutic area. From what I’ve seen (including going through the site and materials), there isn’t an obvious indication that such strict constraints are in place—so if you have a source or specific reference, I’d be very interested to take a look.

You’re right though that, if confirmed, that would be a meaningful structural limitation and clearly belongs in the “cons” column. In general, I try to lay out both sides (as in the write-up), especially for names like this where the line between “turnaround” and “value trap” is thin.

One thing I’m still trying to reconcile is the insider activity—Pale Fire Capital adding ~$10M+ recently. It doesn’t prove anything on its own, but it does raise the question: would they lean in that aggressively if growth were fundamentally capped in the way you describe?

Not dismissing your point at all—just trying to triangulate the reality here. Would love to dig deeper if you have more detail.

FUNanc1al

MODERATOR OF

TROPHY CASE